Abstract
Swollen piglet disease is a significant intestinal infection caused by Escherichia coli, which poses a danger to animals and birds that act as reservoirs for the pathogen. The source of the pathogen in piglets is believed to be sick and over-infected animals or latent bacterial carriers, which form the continuous epizootic chain. Therefore, live vaccines are considered promising for avoiding of swollen piglet disease. This article aims to present the production trials of an attenuated vaccine from the E. coli AC-16 strain, which is currently being developed as a potential solution for preventing escherichiosis. The live attenuated vaccine demonstrated stable residual virulence and activity control when tested on laboratory animals (white mice). In total, 1364 piglets and 262 cows were vaccinated from 2020 to 2022. Piglets from the vaccinated swine were born viable and did not fall ill with escherichiosis. During this period, no cases of illness or death of calves from escherichiosis were reported.